Schedule III Is Here — But Only for Medical. What Happens Next?
Back to Journal

Schedule III Is Here — But Only for Medical. What Happens Next?

May 7, 202614 min read0 comments
News & Policy
Jamie

Jamie

Head Cultivator

On April 22, 2026, the DEA made a big move — they shifted some cannabis products from Schedule I to Schedule III. This is the biggest federal cannabis policy change in 50 years. But the change is narrow. It only covers FDA-approved cannabis drugs and state-licensed medical cannabis. Recreational use stays in Schedule I. For medical patients and licensed operators, this brings real benefits: tax relief, possible pharmacy access, and less federal stigma. For everyone else in the industry and adult-use consumers, the federal war on weed continues unchanged. Here's exactly what changed, what didn't, and what's coming next.

What Actually Changed on April 22, 2026? #

The DEA moved FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III. This gets rid of the 280E tax rule for medical-only operators — but recreational use stays in Schedule I. The change took effect April 22, 2026. It's the biggest federal cannabis policy shift since 1970. The Federal Register published the final order on April 28, 2026, creating two paths to Schedule III status:

Pathway 1: FDA-Approved Cannabis Products #

Any drug product containing cannabis that has received FDA approval is now Schedule III. This includes:

  • Epidiolex (CBD isolate for epilepsy) — already FDA-approved, now formally Schedule III
  • Syndros/Marinol (synthetic THC) — already Schedule III, unchanged
  • Future FDA-approved cannabis drugs — will enter at Schedule III instead of Schedule I

This path is simple. These are drug products that went through clinical trials and FDA review. They're now treated like other Schedule III substances: Tylenol with codeine, ketamine, and anabolic steroids.

Pathway 2: State-Licensed Medical Cannabis #

The more significant change: naturally-derived cannabis (flower, extracts, THC) produced under state medical marijuana licenses is now Schedule III. This covers:

  • State-licensed dispensary products sold to medical cardholders
  • Medical cannabis cultivation, processing, and distribution under state license
  • The entire supply chain, from seed to sale, when conducted under state medical authority

This is where the real impact hits. State-legal medical cannabis operations — including Michigan's licensed medical program and Detroit-based facilities like Divine Toke's sun-grown organic operation — are no longer committing a felony under federal law. But only if they stay strictly within medical boundaries.

What Stayed in Schedule I? #

Adult-use recreational cannabis, home growing without a medical card, gray market sales, interstate commerce, and synthetic cannabinoids all remain Schedule I federal crimes. The DEA's order explicitly excluded "marijuana-derived products for non-medical purposes" from rescheduling. This keeps the federal war on weed going for anyone operating outside state-licensed medical boundaries. Here's what stays illegal:

Activity Status After April 22, 2026
Adult-use/recreational cannabis Schedule I — still federally illegal
Home growing for personal use (non-medical) Schedule I — still federally illegal
"Gift" economies and gray market sales Schedule I — still federally illegal
Interstate cannabis commerce Schedule I — still federally illegal
Synthetically-derived cannabinoids (Delta-8, Delta-10) Schedule I — explicitly excluded
Hemp-derived Delta-9-THC over 0.3% Schedule I — still non-compliant with Farm Bill

This distinction matters. The DEA's order specifically excluded "marijuana-derived products for non-medical purposes" from rescheduling. If you buy cannabis without a medical card — even in a state with adult-use laws — that purchase is still a federal crime. State law may permit it, but federal law does not.

How Does Schedule III Affect Cannabis Taxes? #

Medical-only cannabis operators can now deduct normal business expenses like rent, payroll, and utilities. This drops their effective tax rates from 70-90 cents on the dollar to 21-35 cents. IRS Code 280E — a tax rule from 1982 — previously blocked all standard deductions for Schedule I and II substances. But Schedule III substances are exempt. For a Michigan operator making $5 million per year, this change can mean $1-2 million in annual tax savings.

What Is 280E? #

Section 280E of the Internal Revenue Code is a tax rule that blocks businesses selling Schedule I or II controlled substances from deducting normal business expenses. Congress passed it in 1982 after a cocaine dealer claimed tax deductions. The law was later used against state-legal cannabis businesses.

The result: cannabis businesses paid 70-90 cents of every dollar in taxes because they could only deduct cost of goods sold. They couldn't write off rent, salaries, marketing, or any other operating expense. Imagine you run a pizza shop but can't deduct the cost of cheese, ovens, or rent on your taxes. That's what cannabis businesses faced. This single rule made legal cannabis operations less profitable than illegal ones for nearly 20 years.

What Changes Now #

Schedule III substances are NOT subject to 280E. For medical-only cannabis operators, this means:

  • They can now deduct normal business expenses — rent, payroll, utilities, insurance, marketing
  • Tax rates drop from 70-90 cents on the dollar to 21-35 cents — the same range as normal businesses
  • They can go back and claim money they were owed — operators may amend recent returns to claim deductions previously denied
  • They can now claim tax credits — research credits, opportunity zone credits, and other tax incentives previously blocked

For a mid-sized Michigan medical cannabis operation making $5 million per year, this could mean $1-2 million in annual tax savings. That's enough to expand, hire more workers, or invest in sustainable growing practices. At Divine Toke in Detroit, these savings help us keep our promise to living soil cultivation and Sun+Earth practices that put plant health first.

The Catch: Strict Medical Separation Required #

The 280E relief applies ONLY to medical cannabis operations. If a business sells to both medical and recreational customers — as most Michigan dispensaries do — they must keep the two sides strictly separate:

  • Separate inventory tracking for medical vs. adult-use products
  • Separate accounting for medical vs. adult-use revenue streams
  • Possibly separate legal entities for the two sides of the business

This is complex to manage. Many operators will need new accounting systems, new point-of-sale setups, and legal restructuring to capture the full benefit without risking federal exposure on the adult-use side.

Will Medical Cannabis Move to Pharmacies? #

Not yet — pharmacy dispensing needs FDA-approved products, pharmacies registered with the DEA, and insurance coverage decisions. These are 1-3 years away. State-licensed dispensaries remain the only legal place to buy as of May 2026. The DEA has opened a 60-day registration window for medical entities to apply for federal DEA registration. This suggests the earliest pharmacy access would be late 2026 or early 2027 — and only for pharmaceutical-grade products like Epidiolex.

The Regulatory Framework #

Schedule III substances can be "available by prescription." This means:

  • Doctors registered with the DEA can prescribe (not just recommend) cannabis
  • Pharmacists registered with the DEA can dispense it
  • Standard prescription rules apply — specific dosing, duration, and monitored refills
  • Insurance coverage becomes possible — though not guaranteed

What's Required for Pharmacy Sales #

For medical cannabis to actually show up in CVS or Walgreens, several things must happen:

  1. FDA approval of specific cannabis products — currently only Epidiolex qualifies
  2. Standard dosing and formulation — pharmacy dispensing requires consistent products
  3. Insurance coding and coverage decisions — private insurers and CMS must decide to cover it
  4. State law alignment — many state medical programs operate outside pharmacy regulatory frameworks

The Current Reality #

As of May 2026, pharmacy dispensing of medical cannabis is not happening yet. State-licensed dispensaries remain the only legal place to buy. The DEA has set up a 60-day registration window for state-licensed medical entities to apply for federal DEA registration. The DEA promises to review applications within six months. This suggests the earliest pharmacy access would be late 2026 or early 2027 — and only for products that meet drug safety standards.

What This Means for Patients #

Short term: No immediate change. You'll still buy from dispensaries with a medical card. The products, the process, and the people stay the same.

Medium term: A split is likely. FDA-approved pharmaceutical cannabis (Epidiolex, future drugs) will probably move to pharmacies. Whole-plant cannabis grown in living soil under natural sunlight — the kind Detroit's Divine Toke specializes in — may stay in dispensaries to preserve the craft quality that patients rely on.

Long term: Uncertain. If major insurers start covering cannabis, pharmacy access becomes more likely. If the industry resists standardization to preserve craft cultivation methods, dispensaries may remain the main channel indefinitely.

What's Coming at the June 29 DEA Hearing? #

The DEA will hold a formal meeting where the government hears arguments about rescheduling all marijuana — including adult-use recreational cannabis. A final decision is expected late 2026 or early 2027. This hearing represents the next phase of federal policy evolution. The DEA will examine scientific evidence on abuse potential, agreements with other countries, and public health data. Possible outcomes range from full Schedule III rescheduling (eliminating 280E for all operators) to keeping the current medical-only order.

The Administrative Hearing #

On June 29, 2026, the DEA will hold a formal meeting to consider broader rescheduling of all marijuana to Schedule III — including adult-use/recreational cannabis. This hearing will consider:

  • Scientific evidence on abuse potential and accepted medical use
  • Agreements with other countries (Single Convention on Narcotic Drugs)
  • Public health and safety data
  • Expert testimony from medical, legal, and law enforcement perspectives

Possible Outcomes #

Outcome Probability Impact
Full rescheduling to Schedule III Moderate All cannabis Schedule III — eliminates 280E for all operators, ends federal criminalization
Partial rescheduling (medical only affirmed) Likely Current order stands, recreational stays Schedule I
No change after hearing Possible Current order challenged in court, uncertainty continues
Descheduling (Schedule I removal entirely) Low Would treat cannabis like alcohol, requires Congressional action for full regulation

Timeline Expectations #

These formal hearings typically take 6-12 months from start to final rule. The June 29, 2026 hearing marks the first time the DEA has formally reconsidered cannabis scheduling since the 1970 Controlled Substances Act. If the DEA moves quickly, a final decision on broader rescheduling could come in late 2026 or early 2027. Legal challenges from anti-cannabis groups or states could delay implementation further.

What Should Michigan Patients and Operators Do Now? #

Medical patients should keep using their cards at licensed dispensaries. Operators must immediately talk to cannabis-specialized CPAs to capture 280E deductions and possibly restructure their businesses. The April 2026 order creates immediate tax opportunities for medical-only businesses. It also creates complex compliance challenges for operators serving both medical and recreational markets. Here's the breakdown by stakeholder:

For Medical Patients #

Nothing urgent. Your medical card still works the same way. Same dispensaries, same products, same process. Future benefits to watch for:

  • Insurance coverage (unlikely before 2027)
  • Pharmacy access (unlikely before 2027)
  • Lower prices (possible if 280E relief allows operators to reduce costs)

For Medical-Only Operators #

Act now on tax strategy. Talk to a cannabis-specialized CPA about:

  • Amending recent returns to claim 280E-blocked deductions
  • Restructuring accounting to capture full Schedule III benefits
  • Keeping medical and adult-use sides strictly separate if you serve both markets

This is potentially the biggest financial change in the industry's history. Operators who move fast will capture millions in savings. Those who wait may miss the window to go back and claim money they were owed.

For Adult-Use Operators #

No immediate relief. You still face 280E taxes. Consider:

  • Creating a separate medical entity to capture Schedule III benefits on that side
  • Advocating for the June 29 hearing to result in full rescheduling
  • Preparing accounting systems for potential sudden 280E relief if broader rescheduling happens

For Dispensaries Serving Both Markets #

Complex compliance ahead. You'll need to:

  • Implement separate inventory tracking systems
  • Restructure sales data to clearly separate medical from recreational
  • Possibly create separate legal entities
  • Train staff on the distinction

The penalties for getting this wrong could include loss of Schedule III status, federal prosecution for the adult-use side, and massive tax liability. Get legal and accounting help now.

What Are the International Implications? #

Schedule III status satisfies U.S. agreements with other countries under the 1961 Single Convention on Narcotic Drugs. It also encourages global medical cannabis research and may prompt similar rescheduling in other nations. The change reinforces the medical/adult-use distinction as a global norm. It reduces stigma internationally. But it does not immediately open international trade — Schedule III substances still require import/export permits. Here's how the rescheduling echoes globally:

Impact Area Effect of U.S. Schedule III Status
Treaty Compliance Satisfies 1961 Single Convention requirements without renegotiation
Global Research Encourages medical cannabis studies by reducing stigma
International Policy May prompt similar rescheduling in treaty-compliant nations
Trade No immediate change — import/export permits still required
Norm Setting Reinforces medical/recreational distinction globally

Treaty Obligations #

The United States is party to the 1961 Single Convention on Narcotic Drugs. This is an agreement with other countries that requires cannabis to be controlled. Schedule III satisfies this obligation — it's still a controlled substance, just less strictly controlled. Full descheduling would require renegotiating the treaty or filing a formal reservation. This is why most experts expect Schedule III (not full descheduling) as the ultimate U.S. position.

Global Market Effects #

Other countries watch U.S. scheduling closely. Canada fully legalized without international penalty, but most nations are more cautious. U.S. Schedule III status:

  • Encourages medical cannabis research globally by reducing stigma
  • May prompt similar rescheduling in treaty-compliant nations
  • Reinforces the medical/adult-use distinction as a global norm
  • Does not immediately open international trade — Schedule III substances still require import/export permits

What Are Common Misconceptions About Schedule III? #

Many people wrongly believe cannabis is now fully federally legal, that recreational users don't need medical cards, or that interstate commerce is coming soon — all false. Schedule III maintains strict boundaries between medical and non-medical use. Most day-to-day realities remain unchanged for now. Here are the facts behind the most common misunderstandings:

Misconception The Reality
"Cannabis is now federally legal" False. Schedule III substances remain controlled — ketamine and anabolic steroids are Schedule III too. Medical use is permitted; recreational remains criminalized.
"I don't need a medical card anymore" False. Adult-use cannabis is still Schedule I. Your medical card provides federal protection under the new classification.
"Dispensaries will become pharmacies" False for now. State-licensed dispensaries remain the only legal purchase point. Pharmacy access requires FDA-approved products and DEA registration — 1-3 years away minimum.
"280E is dead for everyone" False. Only medical-only operators get 280E relief. Adult-use and mixed operators still face the tax burden.
"Interstate commerce is coming soon" False. Interstate commerce requires DEA registration and likely federal legislation. Don't expect California cannabis in Michigan dispensaries anytime soon.

FAQ: Schedule III Cannabis Rescheduling #

Q: What changed on April 22, 2026? #

A: The DEA rescheduled FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III, effective April 22, 2026. Adult-use/recreational cannabis remains Schedule I. This change eliminates the 280E tax burden for medical-only operators. It also opens the path for pharmacy dispensing of pharmaceutical cannabis products.

A: Schedule III means cannabis is a controlled substance with accepted medical use. It does NOT mean cannabis is fully legal. Medical cannabis is now regulated like other prescription medications (ketamine, Tylenol with codeine). Recreational cannabis remains illegal under federal law.

Q: Can I buy cannabis at a pharmacy now? #

A: Not yet. Pharmacy dispensing requires FDA approval of specific cannabis products, DEA registration of pharmacies, and insurance coverage decisions. State-licensed dispensaries remain the legal place to buy for the foreseeable future.

Q: What is 280E and why does Schedule III matter for taxes? #

A: IRS Code 280E is a tax rule that blocks businesses selling Schedule I or II substances from deducting normal business expenses. Schedule III substances are not subject to 280E. Medical cannabis operators can now deduct rent, payroll, utilities, and other expenses. This potentially reduces effective tax rates from 70-90 cents on the dollar to 21-35 cents.

Q: Do I still need a medical card? #

A: Yes, if you want federal legal protection. Adult-use cannabis remains Schedule I. Your medical card shows that you're buying under state-licensed medical authority. This is now recognized at Schedule III instead of Schedule I.

Q: What happens at the June 29, 2026 DEA hearing? #

A: The DEA will hold a formal meeting to consider broader rescheduling of all marijuana to Schedule III — including adult-use cannabis. This could result in full rescheduling (280E relief for all operators, end of federal criminalization for possession). Or it could affirm the current medical-only order. Or there could be no change. A final decision is expected in late 2026 or early 2027.

Q: Will my insurance cover medical cannabis now? #

A: Not yet. Insurance coverage requires FDA approval of specific products, established dosing protocols, and insurer decisions to include cannabis in formularies. This process will take 1-3 years minimum. It will likely start with pharmaceutical products like Epidiolex before covering whole-plant cannabis.

Q: I'm a Michigan medical patient. What should I do differently? #

A: Nothing immediately. Keep using your medical card at licensed dispensaries. Future benefits may include insurance coverage and pharmacy access, but these are 1-3 years away. You may see lower prices if 280E relief allows operators to reduce costs.

Q: Why is recreational cannabis still Schedule I? #

A: The DEA's April 2026 order explicitly excluded "marijuana-derived products for non-medical purposes." The medical/adult-use distinction matters legally under international drug treaties and U.S. domestic policy. Changing adult-use status requires the separate June 2026 formal hearing process.

Q: What does this mean for the black market? #

A: Short term, minimal impact. The price gap between legal medical and illegal cannabis will persist or widen as medical operators capture tax savings. Long term, if full rescheduling happens and prices drop in legal markets, the economic incentive for black market activity decreases. But enforcement resources may shift from medical to recreational markets.

Divine Toke is a Detroit-based licensed medical cannabis facility growing sun-grown organic flower in living soil at $15/eighth and $115/ounce. We're actively restructuring to capture Schedule III benefits for our medical patients while keeping the medical and recreational sides strictly separate. For clean, affordable cannabis grown under Sun+Earth practices, shop our medical menu or speak with our team in-store.

Related Reading:

Share